BCY LifeSciences Inc. Signs Licencing Agreement
In announcing the signing of the agreement, Lorne Meikle, BCY's President & CEO commented "The agreement validates our Phase II results and means that if further clinical development is successful, patients suffering from CF and other respiratory disorders will have a new hope for managing their condition. This is truly a good news event for the patients, our partners and our shareholders."
The agreement provides for the continued development of DCF 987 with the initial focus remaining on CF. It includes industry- standard up- front and milestone payments as well as royalty payments when DCF 987 is commercialized.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.